CN1720263A - 三聚细胞因子的三聚结合蛋白 - Google Patents

三聚细胞因子的三聚结合蛋白 Download PDF

Info

Publication number
CN1720263A
CN1720263A CNA2003801046587A CN200380104658A CN1720263A CN 1720263 A CN1720263 A CN 1720263A CN A2003801046587 A CNA2003801046587 A CN A2003801046587A CN 200380104658 A CN200380104658 A CN 200380104658A CN 1720263 A CN1720263 A CN 1720263A
Authority
CN
China
Prior art keywords
seq
trimeric
tnfrsf1b
thr
polypeptide according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2003801046587A
Other languages
English (en)
Chinese (zh)
Inventor
T·L·霍尔帝特
M·H·安德森
H·K·奥托
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yimunuoniuke Denmark Corp
Bird Rock Bio Inc
Original Assignee
Roche Bio Denmark AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Bio Denmark AS filed Critical Roche Bio Denmark AS
Publication of CN1720263A publication Critical patent/CN1720263A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CNA2003801046587A 2002-10-29 2003-10-29 三聚细胞因子的三聚结合蛋白 Pending CN1720263A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60/421,807 2002-10-29
DKPA200201634 2002-10-29
DKPA200201634 2002-10-29

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2010101352531A Division CN101899106A (zh) 2002-10-29 2003-10-29 三聚细胞因子的三聚结合蛋白

Publications (1)

Publication Number Publication Date
CN1720263A true CN1720263A (zh) 2006-01-11

Family

ID=35931707

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2003801046587A Pending CN1720263A (zh) 2002-10-29 2003-10-29 三聚细胞因子的三聚结合蛋白

Country Status (6)

Country Link
JP (1) JP4690044B2 (de)
CN (1) CN1720263A (de)
AT (1) ATE505484T1 (de)
DE (1) DE60336746D1 (de)
DK (1) DK1558640T3 (de)
ES (1) ES2367749T3 (de)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103172748A (zh) * 2013-01-29 2013-06-26 中国人民解放军第三军医大学 一种抗恶性淋巴瘤融合蛋白及其制备方法
CN103172746A (zh) * 2011-12-26 2013-06-26 财团法人工业技术研究院 三聚体Fc融合蛋白及其用途
CN111819186A (zh) * 2018-01-10 2020-10-23 综合医院公司 表达嵌合抗原受体的免疫细胞
WO2022089426A1 (zh) * 2020-10-27 2022-05-05 细胞图谱有限公司 外周血样本分析方法和试剂盒

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2729351C (en) * 2008-06-30 2017-01-24 University Of Pennsylvania Fn14/trail fusion proteins
EP3243836A1 (de) * 2016-05-11 2017-11-15 F. Hoffmann-La Roche AG C-terminal-fusionierte antigenbindende moleküle mit ligandentrimer der tnf-familie

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT672141E (pt) * 1992-10-23 2003-09-30 Immunex Corp Metodos de preparacao de proteinas oligomericas soluveis
WO1998056906A1 (en) * 1997-06-11 1998-12-17 Thoegersen Hans Christian Trimerising module
US10183986B2 (en) * 2005-12-15 2019-01-22 Industrial Technology Research Institute Trimeric collagen scaffold antibodies

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103172746A (zh) * 2011-12-26 2013-06-26 财团法人工业技术研究院 三聚体Fc融合蛋白及其用途
CN103172746B (zh) * 2011-12-26 2016-09-21 财团法人工业技术研究院 三聚体Fc融合蛋白及其用途
CN103172748A (zh) * 2013-01-29 2013-06-26 中国人民解放军第三军医大学 一种抗恶性淋巴瘤融合蛋白及其制备方法
CN103172748B (zh) * 2013-01-29 2014-11-05 中国人民解放军第三军医大学 一种抗恶性淋巴瘤融合蛋白及其制备方法
CN111819186A (zh) * 2018-01-10 2020-10-23 综合医院公司 表达嵌合抗原受体的免疫细胞
WO2022089426A1 (zh) * 2020-10-27 2022-05-05 细胞图谱有限公司 外周血样本分析方法和试剂盒

Also Published As

Publication number Publication date
JP2006520318A (ja) 2006-09-07
ES2367749T3 (es) 2011-11-08
DK1558640T3 (da) 2011-07-25
JP4690044B2 (ja) 2011-06-01
DE60336746D1 (de) 2011-05-26
ATE505484T1 (de) 2011-04-15

Similar Documents

Publication Publication Date Title
EP1558640B1 (de) Trimer-proteine zur trimer-zytokine
JP7583767B2 (ja) 血清中半減期の増強のための操作された抗体ｆｃバリアント
CN1250721C (zh) 与mp1受体结合并具有血小板生成活性的模拟二聚体血小板生成素肽
JP6448368B2 (ja) 免疫グロブリンＦｃ変異体
CN1293098C (zh) 多联免疫粘附
CN1526020A (zh) 重组融合蛋白的二聚体、三聚体、四聚体或五聚体的二聚物或寡聚物
CN1310948C (zh) 作为治疗剂的修饰肽
CN115867572B (zh) 用于增加治疗剂在犬中的半衰期的组合物和使用方法
CN1678634A (zh) 免疫球蛋白单个变体抗原结合区及其特异性构建体
CN1829739A (zh) 结晶肿瘤坏死因子受体2多肽
CN1531545A (zh) 降低融合蛋白的免疫原性
TW201817744A (zh) 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
JP2018503379A (ja) サイトカイン融合タンパク質
JP4660092B2 (ja) 組換えポリペプチド
TW202337911A (zh) 四面體抗體
US20230265146A1 (en) Cytokine conjugates
CN1720263A (zh) 三聚细胞因子的三聚结合蛋白
CN101065401A (zh) 骨保护素变异蛋白
Zhan et al. Fusion of HSA influences TNF-α neutralizing activity of shTNFRs
CN117043190A (zh) 延长治疗剂在家畜动物中的半衰期的组合物和使用方法
CN1745102A (zh) 特异性针对配体及其受体的双特异性单区抗体
CN1738835A (zh) 采用imac纯化tnf结合蛋白的方法
HK1090931A (en) Modified peptides as therapeutic agents
HK1090654A (en) Modified peptides as therapeutic agents

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: BOREAN PHARMA AS

Free format text: FORMER OWNER: ROCHE BIOLOGICAL DENMARK CO., LTD.

Effective date: 20070323

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20070323

Address after: Aarhus

Applicant after: Brian Pharmaceutical Pte. Ltd.

Address before: Aarhus

Applicant before: Roche biological Denmark Ltd.

ASS Succession or assignment of patent right

Owner name: ARNAFURT CO., LTD.

Free format text: FORMER OWNER: IMUNORIC DENMARK CO., LTD.

Effective date: 20081010

Owner name: IMUNORIC DENMARK CO., LTD.

Free format text: FORMER OWNER: BOREAN PHARMA AS

Effective date: 20081010

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20081010

Address after: American California

Applicant after: ANAPHORE, Inc.

Address before: Copenhagen

Applicant before: Yimunuoniuke Denmark Corp.

Effective date of registration: 20081010

Address after: Copenhagen

Applicant after: Yimunuoniuke Denmark Corp.

Address before: Aarhus

Applicant before: Brian Pharmaceutical Pte. Ltd.

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20060111